Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage
A Randomized, Double-Blind, Placebo-Controlled Trial of Methyl Aminolevulinate + Aktilite in Patients With Facial Photodamage
1 other identifier
interventional
49
1 country
1
Brief Summary
The aim of the study is to determine the efficacy of MAL + Aktilite versus placebo + Aktilite in facial photodamage in a randomized double blind trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Feb 2008
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2008
CompletedFirst Submitted
Initial submission to the registry
February 25, 2008
CompletedFirst Posted
Study publicly available on registry
March 6, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2009
CompletedMarch 16, 2009
March 1, 2009
11 months
February 25, 2008
March 13, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Efficacy in facial global photodamage
8 months
Secondary Outcomes (3)
Facial fine lines, mottled pigmentation, tactile roughness, sallowness, erythema, telangiectasia
12 months
Histological effect of MAL+PDT in fibrosis and new collagen formation
12 months
Safety and tolerance
12 months
Study Arms (2)
A
ACTIVE COMPARATORB
PLACEBO COMPARATORInterventions
Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
Eligibility Criteria
You may qualify if:
- Female subjects older than 35 years of age and less than 75 years of age
- Subjects with a photodamage grade of 2 or 3 according to a modified Dover´s Global photodamage scale
- Subjects willing to participate according to protocol requirements.
- Patients with signed Informed Consent
You may not qualify if:
- Pregnant or nursing females.
- Subjects with suspected porphyria, Systemic or cutaneous erythematosus lupus, or any other photosensitizing disorder or drug induced photosensitization.
- Any active infectious skin disorder ( Herpes simplex, molluscum contagiosum, facial warts )
- Subjects with less than 6 months of previous rejuvenation interfering treatments
- Subjects requiring concurrent treatment that would interfere with study objectives and/or assessments.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universidad de Antioquialead
- Galderma R&Dcollaborator
Study Sites (1)
IPS Universitaria - Universidad de Antioquia
Medellín, Antioquia, 01, Colombia
MeSH Terms
Interventions
Study Officials
- PRINCIPAL INVESTIGATOR
Gloria Sanclemente, Dr
Coordinator Group of Investigative Dermatology-GRID
- STUDY CHAIR
Hector I Garcia, Dr.
Coordinator GRAEPIC
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 25, 2008
First Posted
March 6, 2008
Study Start
February 1, 2008
Primary Completion
January 1, 2009
Study Completion
March 1, 2009
Last Updated
March 16, 2009
Record last verified: 2009-03